6 enrolling by invitation. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Enrolling by invitation 6 |
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation Required Field - Ischemic Stroke | Phase 1 / Phase 2 | Enrolling by invitation | Taipei Hospital, Ministry of Health and Welfare | 9 | 2026-08-20 | 2026-08-25 |
| A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia BHV-7000, Placebo - Familial Erythromelalgia | Phase 1 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 5 | 2026-01-15 | 2026-04-08 |
| A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury Metformin - Hypoxic-Ischemic Encephalopathy, HIE | Phase 1 | Enrolling by invitation | Boston Children's Hospital | 30 | 2025-10-01 | 2026-02-17 |
| Intra-arterial Selective Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml)., Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml)., Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml). - Acute Ischemic Stroke | Phase 1 / Phase 2 | Enrolling by invitation | Capital Medical University | 42 | 2025-09-15 | 2026-08-13 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease ADI-001, Fludarabine, Cyclophosphamide - Lupus Nephritis, Autoimmune Diseases | Phase 1 | Enrolling by invitation | Adicet Therapeutics | 180 | 2024-11-10 | 2026-03-19 |
Ischemic Stroke (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1) · Autoimmune Diseases (1) · Behcet Syndrome (1) · Brain Injuries (1) · Channelopathies (1) · Dermatomyositis (1) · Erythromelalgia (1) · Generalized Epilepsy With Febrile Seizures Plus, 7 (1) · Hypoxia-Ischemia, Brain (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Myositis (1) · Neuralgia (1)
Cardiovascular Diseases (6) · Nervous System Diseases (6) · Central Nervous System Diseases (4) · Brain Diseases (3) · Cerebrovascular Disorders (3) · Neuromuscular Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Connective Tissue Diseases (2) · Immune System Diseases (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Pathologic Processes (2) · Skin Diseases (2)
Cyclophosphamide (1) · Metformin (1) · fludarabine (1)
Adicet Therapeutics (1) · Biohaven Therapeutics Ltd. (1) · Boston Children's Hospital (1) · Capital Medical University (1) · Chugai Pharmaceutical (1) · Taipei Hospital, Ministry of Health and Welfare (1)
United States (3) · Taiwan (2) · Australia (1) · Austria (1) · Bulgaria (1) · Canada (1) · China (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1)
Brian Kalish, MD (1)